Medicines and Healthcare products Regulatory Agency
UK regulator for medicines, medical devices and blood components.
Last refreshed: 1 May 2026 · Appears in 1 active topic
How will the MHRA's orbital GMP framework shape the emerging global space pharma industry?
Timeline for Medicines and Healthcare products Regulatory Agency
Co-published pathway for space-manufactured drugs naming BioOrbit as pioneering case
UK Startups and Innovation: BioOrbit raises £9.8m for orbital pharma- What is the MHRA and what does it regulate?
- The Medicines and Healthcare products Regulatory Agency is the UK's independent regulator for medicines, medical devices and blood components. It issues marketing authorisations, sets safety standards, and has operated independently from the EU's EMA since Brexit.Source: Lowdown reporting
- Why was the MHRA involved in the UK's space drugs regulatory pathway?
- The MHRA's involvement was required because any drug manufactured in space for UK market use must meet MHRA licensing and Good Manufacturing Practice standards. The agency co-authored the 5 March 2026 framework with the UK Space Agency, Regulatory Innovation Office and CAA to provide that regulatory clearance route.Source: Lowdown reporting
- Is the MHRA different from the EU's EMA after Brexit?
- Yes. Post-Brexit, the MHRA operates as an independent regulator issuing separate UK marketing authorisations. EU EMA approvals are no longer automatically recognised in the UK; companies must seek a parallel MHRA licence for UK market access.Source: Lowdown reporting
Background
The Medicines and Healthcare products Regulatory Agency (MHRA) co-authored a landmark regulatory pathway on 5 March 2026 alongside the UK Space Agency, the Regulatory Innovation Office, and the Civil Aviation Authority, creating the world's first framework for approving space-manufactured drugs for UK market use. The pathway named BioOrbit as the pioneering commercial case . The document was a regulatory precondition for BioOrbit's £9.8m seed round six weeks later.
Founded in 2003 from the merger of the Medicines Control Agency and the Medical Devices Agency, the MHRA is the UK's independent regulator for medicines, medical devices and blood components. It operates under the Medicines Act 1968 and the Human Medicines Regulations 2012. Post-Brexit, the MHRA operates separately from the European Medicines Agency (EMA), issuing its own marketing authorisations and setting independent safety standards for the UK market. The agency became more strategically significant after Brexit removed automatic UK recognition of EMA approvals, requiring companies to seek a separate UK licence.
The space-pharma pathway is the MHRA's most visible venture into frontier regulatory territory since its post-Brexit independence. It extends the agency's jurisdiction from terrestrial manufacturing to orbital facilities, requiring new guidance on how pharmaceutical GMP (Good Manufacturing Practice) standards apply in microgravity. The pathway's significance reaches beyond BioOrbit: it is a regulatory template that any space-manufactured pharmaceutical company would need to follow for UK market access. The Regulatory Innovation Office co-authorship signals the pathway was designed with active participation from the cross-sector sandbox office rather than retrospective compliance review.